Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Marker Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MRKR
Nasdaq
8731
https://markertherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Marker Therapeutics Inc
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
- Mar 25th, 2024 9:45 pm
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Mar 22nd, 2024 4:30 pm
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
- Jan 22nd, 2024 12:30 pm
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
- Jan 8th, 2024 2:31 pm
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
- Jan 8th, 2024 1:24 pm
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
- Dec 21st, 2023 4:00 pm
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
- Dec 11th, 2023 12:00 pm
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 10:00 pm
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
- Oct 11th, 2023 2:27 pm
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 30th, 2023 12:00 pm
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
- Aug 25th, 2023 4:07 pm
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
- Aug 17th, 2023 1:03 pm
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 14th, 2023 8:30 pm
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
- Aug 7th, 2023 11:00 am
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
- Jul 26th, 2023 11:00 am
Marker Therapeutics (NASDAQ:MRKR) hikes 26% this week, taking one-year gains to 95%
- Jul 22nd, 2023 12:12 pm
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
- Jul 10th, 2023 11:00 am
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
- Jun 26th, 2023 11:00 am
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
- Jun 12th, 2023 11:00 am
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
- May 31st, 2023 10:30 am
Scroll